EVALUATION OF CLINICAL CHARACTERISTICS OF ACUTE SIXTH NERVE PALSY AND STRABISMUS TREATMENT OUTCOMES WITH BOTULINUM TOXIN A INJECTION
Main Article Content
Abstract
Objective: To evaluate the clinical characteristics and therapeutic outcomes of Botulinum Toxin A (BTA) injection into the medial rectus muscle for acute acquired sixth nerve palsy (< 6 months).
Methods: A prospective interventional study was conducted on 14 patients (14 eyes) with acute sixth nerve palsy treated with BTA injection (BOTOX®, 3,0–6.0 UI) at the Vietnam National Institute of Ophthalmology. Ocular deviation (D1), abduction deficit, diplopia, and abnormal head posture were evaluated at baseline (T0), 1 week (T1), 1 month (T2), and 3 months (T3).
Results: Mean age was 52.5 ± 18.2 years; mean onset duration was 1.23 ± 0.65 months. Microvascular etiology accounted for 57.1%, trauma for 28.6%. All patients experienced binocular horizontal diplopia; 42.9% exhibited compensatory face turn. Median baseline esotropia (D1) was 25.0 PD (IQR: 18.0–35.0 PD). At 3 months post-injection, median D1 significantly decreased to 0.0 PD (p < 0.001); 71.4% (10/14 eyes) achieved alignment (D1 ≤ 10 PD). Improved abduction was observed in 92.9% of eyes (71.4% improved by ≥ 2 grades). Diplopia resolved in 71.4% in primary position. Overall success rate was 71.4%; subsequent strabismus surgery in unsuccessful cases increased two-step success rate to 92.9%. Transient mild side effects occurred in 14.3% (ptosis, lagophthalmos) and resolved within 2 weeks.
Conclusion: Chemodenervation with Botulinum Toxin A is a safe, minimally invasive, and effective procedure for acute sixth nerve palsy, providing rapid relief of diplopia and alignment restoration.
Keywords
Sixth nerve palsy, Botulinum Toxin A, acquired esotropia, diplopia
Article Details
References
2. Cleveland Clinic (2023). Sixth Nerve Palsy: Causes, Symptoms & Treatment. Cleveland Clinic Health Library.
3. Khalili M.R., Razeghinejad M.R., et al (2024). Botulinum Toxin Injection for the Treatment of Third, Fourth, and Sixth Nerve Palsy: A Meta-Analysis. Journal of Pediatric Ophthalmology & Strabismus, 61(1), 24-33.
4. Rowe F.J., Noonan C.P. (2023). Botulinum toxin for the treatment of strabismus. Cochrane Database of Systematic Reviews, Issue 3.
5. Wong E.S., Wong V.A., et al (2018). Botulinum toxin as an initial therapy for management of sixth nerve palsies. Hong Kong Journal of Ophthalmology, 22(2), 45-50.
6. Kim HJ, Kim HJ, Choi JY, Yang HK, Hwang JM, Kim JS (2023) Etiologic distribution of isolated abducens nerve palsy: Analysis of 807 patients and literature review. Eur J Neurol.30(8), 2471-2480.
7. Rowe FJ, Noonan CP. (2017) Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev. 3(3)
8. Hung HL, Kao LY, Sun MH. (2005) Botulinum toxin treatment for acute traumatic complete sixth nerve palsy. Eye Lond. 19(3):337-341.